Table 2.
Gabapentinoid prescribing patterns and pathways 1997–2019, meta-analysis of CPRD GOLD and AURUM data.
| Gabapentin | Pregabalin | |
|---|---|---|
| Dose and treatment duration | ||
| Median (IQR) dose (mg) | 977 (477, 1799) | 186 (121, 374) |
| Median (IQR) treatment duration (months) | 2.81 (0.95, 13.12) | 4.18 (0.92, 19.66) |
| Prescribing pathway in 12 months prior to index date (percentage (95% CI)) | ||
| Simple analgesics (paracetamol, nefopam) | 25.9 (25.8, 26.0) | 27.6 (27.5, 27.8) |
| Opioids | 64.9 (64.8, 65.0) | 64.6 (64.5, 64.8) |
| NSAIDs | 47.1 (47.0, 47.2) | 45.4 (45.2, 45.5) |
| Topical neuropathic pain treatments | 2.0 (2.0, 2.1) | 2.9 (2.8, 2.9) |
| Duloxetine/Amitriptylinea | 33.7 (33.6, 33.8) | 34.5 (34.3, 34.6) |
| Carbamazepinea | 2.9 (2.8, 2.9) | 2.6 (2.5, 2.6) |
| Concurrent prescriptions (percentage (95% CI)) | ||
| Opioids | 61.0 (60.9, 61.1) | 61.1 (60.9, 61.2) |
| Benzodiazepines | 16.3 (16.2, 16.4) | 21.1 (21.0, 21.2) |
| Z-drugs | 8.2 (8.1, 8.2) | 11.8 (11.7, 11.9) |
| Antidepressants | 48.6 (48.5, 48.8) | 54.8 (54.6, 54.9) |
a
Recommended in the UK NICE Neuropathic Pain Guideline.15